Carlyle Seeks Banks for India IPO of Healthcare RCM Platform Built on Knack-EqualizeRCM

The Quick Take

• Carlyle has begun seeking investment bank pitches for a potential India IPO of its healthcare revenue cycle management platform
• The IPO platform was created through the merger of Knack RCM and EqualizeRCM, both Carlyle-backed entities
• Valuation and issue size remain undecided, but adviser selection is expected soon per Economic Times reporting

Private equity giant Carlyle has begun soliciting investment bank pitches for a potential India IPO of its healthcare revenue cycle management platform — a company created through the strategic combination of two Carlyle-backed entities, Knack RCM and EqualizeRCM. Revenue cycle management, the process of tracking and collecting medical billing revenues from insurance payers and patients, has emerged as a high-growth outsourced services category as US and international healthcare providers seek to reduce administrative costs. India serves as the delivery hub for most large RCM platforms due to its combination of English-language healthcare billing expertise, cost-competitive labor, and large trained workforce.

An India IPO for a Carlyle healthcare RCM platform would follow the PE firm's established playbook of acquiring, scaling, and listing Indian-base business process outsourcing assets on NSE or BSE. The RCM sector in India includes publicly listed peers such as GeBBS Healthcare Solutions, Firstsource Solutions, and Omega Healthcare Management — companies whose valuations provide a pre-IPO comparable set for Carlyle's combined entity. Given that the adviser selection process is at a preliminary stage, a formal IPO is likely 12-18 months away, assuming Carlyle targets a post-adviser market validation and SEBI approval cycle. The merged platform's combined revenue base from Knack and EqualizeRCM will be the primary valuation anchor.

The forward signal is Carlyle's formal investment bank selection announcement, which will trigger the DRHP (Draft Red Herring Prospectus) preparation and SEBI review cycle. Investor attention should focus on the RCM platform's US payer mix, contract renewal rates, and offshore headcount growth as metrics that distinguish premium-multiple healthcare IT services companies from the broader BPO sector. The macro variable is US healthcare reimbursement policy: any changes to CMS Medicare/Medicaid billing rules directly impact the complexity and volume of RCM work outsourced to Indian platforms, affecting revenue growth visibility for the IPO candidate.

Synthesized from 2 sources.